Printer Friendly

ROPAK LABORATORIES ANNOUNCES REPURCHASE AGREEMENT FOR MARKETING RIGHTS SIGNED

 ROPAK LABORATORIES ANNOUNCES
 REPURCHASE AGREEMENT FOR MARKETING RIGHTS SIGNED
 IRVINE, Calif., Nov. 26 /PRNewswire/ -- Ropak Laboratories (NASDAQ: RPKL) announced today that it has signed and consummated a definitive agreement to reacquire all worldwide and distribution rights to its present and future products from Ropak Corp. Marketing rights to the company's EYTEX, SKINTEX, SOLATEX and certain future in vitro tests were awarded to Ropak Corp. in early 1989 when it acquired an equity interest in Ropak Laboratories.
 Ropak Laboratories produces proprietary in vitro tests to evaluate potential irritation and toxicity to humans posed by a wide variety of chemicals and compounds. Its tests provide a cost- effective, rapid and consistent laboratory alternative to live animal testing, enabling household, consumer and industrial products manufacturers to screen new materials and product formulations to assess their safety. The company also distributes throughout North and South America, Europe and the Pacific Rim.
 The company's stock is traded over-the-counter NASDAQ: RPKL and is traded by 14 market makers.
 -0- 11/26/91
 /CONTACT: Fran Daniels of Financial Sciences of America, 310-278-4413, for Ropak Laboratories/
 (RPKL) CO: Ropak Laboratories ST: California IN: MTC SU:


CH-EH -- LA005 -- 7176 11/26/91 09:30 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 26, 1991
Words:196
Previous Article:VOLKSWAGEN BREAKS TRADITION WITH SIX-CYLINDER MODELS -- AND WINS
Next Article:SECURITY ENVIRONMENTAL SYSTEMS INC. ANNOUNCES EXTENSION OF LEASE-OPTION
Topics:


Related Articles
WILLIAM J. FISHER NAMED PRESIDENT AND COO OF ROPAK LABORATORIES
ENDOTRONICS DISCONTINUES DISTRIBUTION AGREEMENT WITH VENTREX LABORATORIES -- SIGNS LETTER OF INTENT WITH NORTHUMBRIA BIOLOGICALS
INSTITUTE FOR LABORATORY MEDICINE SELLS FLORIDA LABORATORY ASSURING COMPLIANCE WITH STARK AMENDMENT
INSTITUTE FOR LABORATORY MEDICINE SELLS FLORIDA LABORATORY ASSURING COMPLIANCE WITH STARK AMENDMENT
ROPAK LABORATORIES DISTRIBUTION AGREEMENT SIGNED WITH TECNOTESTS IN BRAZIL
ROPAK LABORATORIES SIGNS AGREEMENT WITH WORLD'S EIGHTH-LARGEST CHEMICAL AND PHARMACEUTICAL COMPANY
COLUMBIA LABORATORIES SIGNS AGREEMENT TO SHARE TECHNOLOGY WITH INSITE VISION INCORPORATED
HOFFMANN-LA ROCHE AND ABBOTT AGREE TO LICENSE KEY PATENTS FOR DIAGNOSTIC APPLICATIONS OF GENE AMPLIFICATION TECHNOLOGIES
Carrington Laboratories Reports Second Quarter Results, 1997 Six Month Loss Per Share of $0.06 Versus $0.54 in 1996
Transgenomic and Power3 Medical Complete Agreement for Exclusive License of Neurodegenerative Biomarker Test.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters